Multicentre, multinational, randomised, double blind, double dummy, active drug controlled, parallel group study design clinical trial of the efficacy and tolerability of beclomethasone dipropionate 250 mcg [microg] plus salbutamol 100 mcg in HFA pMDI [hydroflurocarbons pressurized metered dose inhaler] fixed combination vs. beclomethasone dipropionate 250 mcg plus salbutamol 100 mcg in CFC pMDI [chloroflurocarbons] (Clenil compositum 250) fixed combination in a 12-week treatment period of adult patients with uncontrolled asthma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Salbutamol/beclometasone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 30 Mar 2017 Biomarkers information updated
- 06 Nov 2012 Planned number of patients changed from 180 to 282.
- 23 Apr 2010 Additional trial location (Russia) identified as reported by ClinicalTrials.gov.